Ex vivo stimulation of immune cells from patients with cancer antigen
2016
Justus-Liebig-University, Giessen, Germany
Anaplastic lymphoma kinase (ALK) in patients with ALK-positive anaplastic large cell lymphoma (ALCL) is an attractive target for immune therapy. In this study, the researchers aimed to evaluate the response of ALK-specific T cells in ALCL patients. The researchers used autologous dendritic cells (DCs) transfected with RNA (IVT-RNA) encoding ALK to be used as antigen-presenting cells for T cell stimulation in vitro. ALK-specific T cell responses were detected in three of five ALK-positive ALCL patients tested. Further analysis of a larger unselected cohort of patients is planned to define whether the strength of the T cell response correlates with the ALK-antibody titre and clinical characteristics.
Analysis of nucleophosmin–anaplastic lymphoma kinase (NPM-ALK)- reactive CD81 T cell responses in children with NPM-ALK1 anaplastic large cell lymphoma
W. Woessmann
Added on: 07-29-2021
[1] https://onlinelibrary.wiley.com/doi/10.1111/cei.12842[2] https://data.jrc.ec.europa.eu/dataset/352f7dfd-05cf-434b-a96a-7e270dc76573
